Tempus stands to earn $200 million in data licensing and model development fees from the collaborations, the release said.

AstraZeneca has rejoined the main U.S. drug lobby group, roughly two years after leaving it, the Pharmaceutical Research and ...

CEO Pascal Soriot said Europe was "falling behind" in attracting investment and needed to "invest more in what really matters ...